India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Shivalik Rasayan, once focused on agrochemicals, has entered pharmaceuticals by acquiring Medicamen Biotech and securing USFDA approval for its new API plant at Dahej-II in 2024.</li>
<li>The company is transforming into a diversified chemicals and pharma player. Investments in R&amp;D, larger agrochemical capacity, and regulated pharma access open pathways for higher-margin and sustainable growth.</li>
<li>Despite past issues of underutilized plants, high costs, and delays, recent approvals and new facilities position Shivalik Rasayan for steadier performance and long-term growth if execution remains strong.</li>
</ul>


Shivalik Rasayan, once focused on agrochemicals, has entered pharmaceuticals by acquiring Medicamen Biotech and securing USFDA approval for its new API plant at Dahej-II in 2024.
The company is transforming into a diversified chemicals and pharma player. Investments in R&amp;D, larger agrochemical capacity, and regulated pharma access open pathways for higher-margin and sustainable growth.
Despite past issues of underutilized plants, high costs, and delays, recent approvals and new facilities position Shivalik Rasayan for steadier performance and long-term growth if execution remains strong.


The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

India

Shivalik Rasayan Limited manufactures agricultural chemicals. The Company produces organophosphorus based insecticides. Shivalik Rasayan serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shivalik Rasayan (SHVK IN)

The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

​Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...

Sudarshan Bhandari

Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...